MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Net increase(decrease) in cash and cash...-$7,666K (-1587.54%↓ Y/Y)Accrued expenses$8,306K Change in fair value ofconvertible notes-$3,705K Stock-based compensation$2,760K (206.90%↑ Y/Y)Inventory-$1,218K Amortization of intangibleassets$1,043K Accretion of interest forroyalty obligations$963K Inventory write-off$925K Depreciation of property andequipment$278K Amortization of debt discount$237K (-8.46%↓ Y/Y)Operating leaseright-of-use assets-$105K Lease amortizationexpense$68K Net cash used inoperating activities-$7,664K (-610.11%↓ Y/Y)Net cash used ininvesting activities-$2K Canceled cashflow$19,608K Net loss-$23,417K (-332.32%↓ Y/Y)Purchases of property andequipment$2K Accounts receivable$2,782K Prepaid expenses$385K (826.98%↑ Y/Y)Accounts payable-$338K Deferred revenue-$183K Operating leaseliabilities-$167K
Cash Flow

Pelthos Therapeutics Inc. (PTHS)

Pelthos Therapeutics Inc. (PTHS)

source: myfinsight.com